NEW YORK (GenomeWeb) – Amoy Diagnostics, Premia Holdings, and Loxo Oncology today announced a partnership aimed at genetic screening of patients for a targeted cancer therapy.
As part of the deal, China-based AmoyDx and Tokyo-headquartered Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development. AmoyDx's multigene PCR and next-generation sequencing panels will be used to identify patients with RET genetic alteration.
Financial and other terms of the agreement were not disclosed.
AmoyDx develops molecular diagnostics products for the Chinese market. Stamford, Connecticut-based Loxo is a wholly owned subsidiary of Eli Lilly developing drugs for patients with genetically defined cancers. Premia, founded in 2018, is the international business development partner for Japan's genome screening project called LC-SCRUM. Its focus is to accelerate new cancer drug development.